Aflibercept

Association of Molar Dose and Early Retinochoroidal Blood Flow Changes After Intravitreal Anti-Vascular Endothelial Growth Factor Therapy.

Journal: Investigative ophthalmology & visual science

Published: January 14, 2026

Anti-VEGF Therapy Switching in Neovascular Age-Related Macular Degeneration: Insights from Automated Volumetric Retinal Fluid Analysis.

Journal: Retina (Philadelphia, Pa.)

Published: January 06, 2026

Cost-effectiveness analysis of early versus late switching in treatment-naïve patients with refractory diabetic macular oedema in the Turkish population: real-world data from the Bosphorus DME study group, report number 5.

Journal: Clinical & experimental optometry

Published: January 06, 2026

Alpha-Gal Syndrome Allergy to Intravitreal Administration of Anti-Vascular Endothelial Growth Factor Agents.

Journal: Journal of vitreoretinal diseases

Published: January 02, 2026

RWC Update: Impact of Aflibercept 2 mg Biosimilars on Retinal Disease Management; Power of the Needle; Proliferative Vitreoretinopathy.

Journal: Ophthalmic surgery, lasers & imaging retina

Published: January 02, 2026

The association between intravitreal injections and glaucoma: an update.

Journal: Current opinion in ophthalmology

Published: December 23, 2025

Analysis the frequency of using Aflibercept (8 mg) in the treatment of neovascular age-related macular degeneration and diabetic macular edema compared with other anti-VEGF agents

Journal: Vestnik oftalmologii

Published: December 23, 2025

Functional and Structural Impact of Switching to Bevacizumab in neovascular-AMD Patients Treated with Aflibercept or Ranibizumab.

Journal: European journal of ophthalmology

Published: December 22, 2025

High-Dose Aflibercept for PCV-Toward Potentially Extended Durability.

Journal: JAMA ophthalmology

Published: December 18, 2025

Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: Post Hoc Analysis of the PULSAR Randomized Clinical Trial.

Journal: JAMA ophthalmology

Published: December 18, 2025

Long-term Visual Outcomes in Pseudoxanthoma Elasticum-associated Choroidal Neovascularization: A National Database Study.

Journal: Ophthalmic surgery, lasers & imaging retina

Published: December 16, 2025

Wirksamkeit von 2 mg gegenüber hochdosierten 8 mg Aflibercept bei neovaskulärer altersbedingter Makuladegeneration

Journal: Klinische Monatsblatter fur Augenheilkunde

Published: December 15, 2025

Association of Molar Dose and Early Retinochoroidal Blood Flow Changes After Intravitreal Anti-Vascular Endothelial Growth Factor Therapy.

Association of Molar Dose and Early Retinochoroidal Blood Flow Changes After Intravitreal Anti-Vascular Endothelial Growth Factor Therapy.

Anti-VEGF Therapy Switching in Neovascular Age-Related Macular Degeneration: Insights from Automated Volumetric Retinal Fluid Analysis.

Anti-VEGF Therapy Switching in Neovascular Age-Related Macular Degeneration: Insights from Automated Volumetric Retinal Fluid Analysis.

Cost-effectiveness analysis of early versus late switching in treatment-naïve patients with refractory diabetic macular oedema in the Turkish population: real-world data from the Bosphorus DME study group, report number 5.

Cost-effectiveness analysis of early versus late switching in treatment-naïve patients with refractory diabetic macular oedema in the Turkish population: real-world data from the Bosphorus DME study group, report number 5.

Alpha-Gal Syndrome Allergy to Intravitreal Administration of Anti-Vascular Endothelial Growth Factor Agents.

Alpha-Gal Syndrome Allergy to Intravitreal Administration of Anti-Vascular Endothelial Growth Factor Agents.

RWC Update: Impact of Aflibercept 2 mg Biosimilars on Retinal Disease Management; Power of the Needle; Proliferative Vitreoretinopathy.

RWC Update: Impact of Aflibercept 2 mg Biosimilars on Retinal Disease Management; Power of the Needle; Proliferative Vitreoretinopathy.

The association between intravitreal injections and glaucoma: an update.

The association between intravitreal injections and glaucoma: an update.

Analysis the frequency of using Aflibercept (8 mg) in the treatment of neovascular age-related macular degeneration and diabetic macular edema compared with other anti-VEGF agents

Analysis the frequency of using Aflibercept (8 mg) in the treatment of neovascular age-related macular degeneration and diabetic macular edema compared with other anti-VEGF agents

Functional and Structural Impact of Switching to Bevacizumab in neovascular-AMD Patients Treated with Aflibercept or Ranibizumab.

Functional and Structural Impact of Switching to Bevacizumab in neovascular-AMD Patients Treated with Aflibercept or Ranibizumab.

High-Dose Aflibercept for PCV-Toward Potentially Extended Durability.

High-Dose Aflibercept for PCV-Toward Potentially Extended Durability.

Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: Post Hoc Analysis of the PULSAR Randomized Clinical Trial.

Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: Post Hoc Analysis of the PULSAR Randomized Clinical Trial.

Long-term Visual Outcomes in Pseudoxanthoma Elasticum-associated Choroidal Neovascularization: A National Database Study.

Long-term Visual Outcomes in Pseudoxanthoma Elasticum-associated Choroidal Neovascularization: A National Database Study.

Wirksamkeit von 2 mg gegenüber hochdosierten 8 mg Aflibercept bei neovaskulärer altersbedingter Makuladegeneration

Wirksamkeit von 2 mg gegenüber hochdosierten 8 mg Aflibercept bei neovaskulärer altersbedingter Makuladegeneration

Wirksamkeit von 2 mg gegenüber hochdosierten 8 mg Aflibercept bei neovaskulärer altersbedingter Makuladegeneration

Wirksamkeit von 2 mg gegenüber hochdosierten 8 mg Aflibercept bei neovaskulärer altersbedingter Makuladegeneration